An Open-Label, Rater-Blinded, Augmentation Study of Aripiprazole in Treatment-Resistant Depression

Abstract

The study indicates the potential utility of aripiprazole as an augmenting agent in treatment-resistant depression, particularly in those who had failed 2 or more antidepressant trials. Adequately powered, randomized controlled trials are necessary to evaluate the role of aripiprazole in treatment-resistant depression.